Pharmaceutical company Mylan NV (NASDAQ:MYL) revealed on Wednesday the availability of Drospirenone and Ethinyl Estradiol Tablets USP in 3 mg/0.02 mg in the US contraceptive market.

According to the company, the Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/0.02 mg is the generic version of Bayer's Yaz Tablets.

The company passed the US Food and Drug Administration's (FDA) final approval for its Abbreviated New Drug Application (ANDA) for the generic generic Yaz Tablets for the prevention of pregnancy as well as for the treatment of acne vulgaris in women at least 14 years of age who have achieved menarche and desire an oral contraceptive for birth control.

For the 12 months ending 28 February 2018, the US sales for the company's Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/0.02 mg was about USD161m, according to IQVIA.

Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use, concluded the company.